Cancer adjuvant chemotherapy strategic classification by artificial neural network with gene expression data: An example for non-small cell lung cancer
暂无分享,去创建一个
Hung-Wen Chiu | Yo-Cheng Chang | Yen-Chen Chen | Wan-Chi Ke | Hung-Wen Chiu | Yen-Chen Chen | Yo-Cheng Chang | Wan-Chi Ke
[1] David E. Misek,et al. Gene-expression profiles predict survival of patients with lung adenocarcinoma , 2002, Nature Medicine.
[2] T. Tio,et al. The TNM staging system. , 1996, Gastrointestinal endoscopy.
[3] G. Scagliotti,et al. The ALPI Trial: The Italian/European Experience with Adjuvant Chemotherapy in Resectable Non–Small Lung Cancer , 2005, Clinical Cancer Research.
[4] Brian Findlay,et al. Randomized phase III trial of vinorelbine plus cisplatin compared with observation in completely resected stage IB and II non-small-cell lung cancer: updated survival analysis of JBR-10. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[5] F. Harrell,et al. Artificial neural networks improve the accuracy of cancer survival prediction , 1997, Cancer.
[6] Igor Jurisica,et al. Gene expression–based survival prediction in lung adenocarcinoma: a multi-site, blinded validation study , 2008, Nature Medicine.
[7] Bengt Bergman,et al. Long-term results of the international adjuvant lung cancer trial evaluating adjuvant Cisplatin-based chemotherapy in resected lung cancer. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[8] Christopher M. Bishop,et al. Neural networks for pattern recognition , 1995 .
[9] Arnoldo Frigessi,et al. BIOINFORMATICS ORIGINAL PAPER doi:10.1093/bioinformatics/btm305 Gene expression Predicting survival from microarray data—a comparative study , 2022 .
[10] David J Sugarbaker,et al. Adjuvant paclitaxel plus carboplatin compared with observation in stage IB non-small-cell lung cancer: CALGB 9633 with the Cancer and Leukemia Group B, Radiation Therapy Oncology Group, and North Central Cancer Treatment Group Study Groups. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[11] T. Bagnyukova,et al. DUSP6 regulates drug sensitivity by modulating DNA damage response , 2013, British Journal of Cancer.
[12] Jeremy J. W. Chen,et al. A five-gene signature and clinical outcome in non-small-cell lung cancer. , 2007, The New England journal of medicine.
[13] Caroline Diorio,et al. Alcohol and HER2 polymorphisms as risk factor for cardiotoxicity in breast cancer treated with trastuzumab. , 2013, Anticancer research.
[14] Seung-Mo Hong,et al. HER2 protein expression and HER2 gene amplification are infrequent in small intestinal carcinomas , 2013, Virchows Archiv.
[15] A. Jemal,et al. Cancer statistics, 2013 , 2013, CA: a cancer journal for clinicians.
[16] Milind B. Suraokar,et al. A 12-Gene Set Predicts Survival Benefits from Adjuvant Chemotherapy in Non–Small Cell Lung Cancer Patients , 2013, Clinical Cancer Research.
[17] Bartomeu Massuti,et al. Predicting Response to Chemotherapy With Early-Stage Lung Cancer , 2011, Cancer journal.
[18] Max S Wicha,et al. HER2 and breast cancer stem cells: more than meets the eye. , 2013, Cancer research.
[19] E. Lander,et al. Classification of human lung carcinomas by mRNA expression profiling reveals distinct adenocarcinoma subclasses , 2001, Proceedings of the National Academy of Sciences of the United States of America.
[20] Hung-Wen Chiu,et al. Risk classification of cancer survival using ANN with gene expression data from multiple laboratories , 2014, Comput. Biol. Medicine.
[21] A. D’Andrea,et al. A DNA Repair Pathway–Focused Score for Prediction of Outcomes in Ovarian Cancer Treated With Platinum-Based Chemotherapy , 2012, Journal of the National Cancer Institute.
[22] C. Leonetti,et al. Dual-specificity phosphatase DUSP6 has tumor-promoting properties in human glioblastomas , 2011, Oncogene.
[23] Sung-Liang Yu,et al. A Four-Gene Signature from NCI-60 Cell Line for Survival Prediction in Non–Small Cell Lung Cancer , 2009, Clinical Cancer Research.
[24] Robert Milroy,et al. O-179 The Big Lung Trial (BLT): Determining the value of cisplatin-based chemotherapy for all patients with non-small cell lung cancer (NSCLC). Preliminary results in the surgical setting , 2003 .
[25] Hideaki Mitsui,et al. Down-regulation of DUSP6 expression in lung cancer: its mechanism and potential role in carcinogenesis. , 2009, The American journal of pathology.
[26] Ryan van Laar,et al. Genomic signatures for predicting survival and adjuvant chemotherapy benefit in patients with non-small-cell lung cancer , 2012 .
[27] P. Gao,et al. Which Is a More Accurate Predictor in Colorectal Survival Analysis? Nine Data Mining Algorithms vs. the TNM Staging System , 2012, PloS one.
[28] Dung-Tsa Chen,et al. Prognostic and predictive value of a malignancy-risk gene signature in early-stage non-small cell lung cancer. , 2011, Journal of the National Cancer Institute.
[29] Ulrike Olszewski,et al. Alterations of phosphoproteins in NCI-H526 small cell lung cancer cells involved in cytotoxicity of cisplatin and titanocene Y. , 2012, Neoplasia.
[30] Sujan Piya,et al. DUSP6 is a novel transcriptional target of p53 and regulates p53‐mediated apoptosis by modulating expression levels of Bcl‐2 family proteins , 2012, FEBS letters.
[31] Igor Jurisica,et al. Prognostic and predictive gene signature for adjuvant chemotherapy in resected non-small-cell lung cancer. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[32] John D. Minna,et al. Non-small-cell lung cancer mRNA expression signature predicting response to adjuvant chemotherapy. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[33] K. P. Sudheer,et al. Short‐term flood forecasting with a neurofuzzy model , 2005 .
[34] Jean-Yves Douillard,et al. Adjuvant chemotherapy for non-small-cell lung cancer: it does not always fade with time. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[35] Angela Greco,et al. DUSP6/MKP3 is overexpressed in papillary and poorly differentiated thyroid carcinoma and contributes to neoplastic properties of thyroid cancer cells. , 2013, Endocrine-related cancer.